Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882066 | 0.92 | HTR6 (0.47) | MAPTCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL2880232 | 0.90 | MAPT (0.62) | MAPTCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL20523685 | 0.89 | RIPK2 (0.45) | MAPTCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL10192149 | 0.84 | CYP11B1 (0.47) | MAPTCYP11B1CYP11B2GAATP53 | |
| SCHEMBL2877335 | 0.81 | MAPT (0.54) | MAPTCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL288153 | 0.80 | NPC1 (0.62) | CYP11B1CYP11B2MEN1KMT2ANPC1 | |
| SCHEMBL2881602 | 0.77 | CYP11B1 (0.56) | MAPTCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL10192176 | 0.75 | RIPK2 (0.46) | MAPTCYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL21630359 | 0.74 | RIPK2 (0.48) | MAPTMEN1KMT2ANPC1GAA | |
| SCHEMBL14068908 | 0.74 | CYP11B1 (0.47) | MAPTCYP11B1CYP11B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234422-A1 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-7750038-B2 | Sulfonylated heterocycles useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2121657-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008109056-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221160-A1 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | GNRHR, FSHR, PRLHR | MAPT 4879/4885CYP11B1 987/4885CYP11B2 1316/4885 |
| US-20100234422-A1 | Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor | GNRHR, FSHR, PRLHR | MAPT 4879/4885CYP11B1 987/4885CYP11B2 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.